ArticleCureus2026
Proton Therapy for Muscle-Invasive Bladder Cancer: Outcomes from the Multicenter Proton Collaborative Group PCG 001-09 Registry Trial.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMuscle-invasive bladder cancer (MIBC) is treated with radical cystectomy or trimodality therapy (TMT), which yield comparable survival outcomes. Many patients undergoing TMT experience significant toxicity related to chemoradiation. The unique physics of proton radiation may allow for a more tolerable regimen. We herein report on the safety and efficacy of proton therapy for patients with MIBC.
methodsPatients with non-metastatic MIBC treated with curative-intent proton radiation were enrolled in the multi-center Proton Collaborative Group (PCG) prospective, observational registry trial. Metastatic or palliatively treated patients were excluded. Baseline characteristics, including patient sex, age, stage, smoking history, and performance status, as well as details of the proton therapy, were documented. The primary endpoints were acute and late adverse events. Locoregional recurrence and overall survival were assessed.
resultsBetween August 2010 and April 2025, 39 adult patients were eligible for analysis. The median age was 78 years (IQR 75-85), and most patients were White (36/39, 92.3%) and male (29/39, 74.4%). Most patients were clinical stage II (23/39, 59.0%). All patients received definitive proton therapy to a median (IQR) dose of 56.8 Gy (55.0-64.8), and 66.6% received concurrent chemotherapy. With a median follow-up of 11 months, there were three local recurrences and 14 deaths, yielding a crude 92.3% local control rate and 64.1% overall survival. The 12- and 24-month actuarial overall survivals using a Kaplan-Meier analysis were 59.0% and 32.7%, respectively. The highest grade of acute genitourinary or gastrointestinal toxicity was grade 3, affecting only 2 (5.1%) and 1 (2.6%) patients, respectively. No late grade 3 or higher toxicities were reported.
conclusionIn the largest prospective cohort of MIBC patients treated with proton therapy reported to date, protons appear to be an effective and well-tolerated radiation modality for those undergoing TMT. This is increasingly important in the present landscape of expanding systemic therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.